Working… Menu

Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00823173
Recruitment Status : Completed
First Posted : January 15, 2009
Last Update Posted : May 26, 2011
Information provided by:

Brief Summary:
The purpose of this study is to determine whether ESBA105, a topically applied TNF-alpha inhibitor, is safe and clinically active when applied to the eye of patients suffering from acute anterior uveitis

Condition or disease Intervention/treatment Phase
Anterior Uveitis Biological: ESBA105 Phase 2

Detailed Description:

Acute anterior uveitis (AAU) is a common, recurrent disease characterized by inflammation of the iris and ciliary body. Though usually effectively treated by topical corticosteroids, novel treatment modalities are required to overcome the limitations and adverse effect problems associated with the use of corticosteroids. TNF-alpha has been recognized as a central disease mediator in AAU, as shown by preclinical models and clinical data with systemically applied TNF-alpha inhibitors.

ESBA105 is a topically applied TNF-alpha inhibitor that is characterized by efficient penetration into the eye resulting in high intraocular drug levels. A recently completed Phase I trial confirmed that safety and tolerability of topical ESBA105 in healthy individuals is excellent and systemic exposure is low.

In this pilot trial, the safety, local tolerability and clinical activity of topical ESBA105 in the treatment of patients with acute anterior uveitis shall be explored.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Exploratory Study to Assess the Safety, Tolerability and Clinical Activity of Topically Applied ESBA105 in Patients With Acute Anterior Uveitis
Study Start Date : January 2009
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Topical ESBA105
ESBA105 applied as eye drops
Biological: ESBA105
ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)

Primary Outcome Measures :
  1. Changes in the level of intraocular inflammation (anterior chamber cell count according to SUN Working group criteria) [ Time Frame: 28 Days ]

Secondary Outcome Measures :
  1. Nature and incidence of adverse events, physical and ophthalmological findings and laboratory test results [ Time Frame: 28 Days ]
  2. Systemic exposure to study drug [ Time Frame: 28 Days ]
  3. Changes in disease severity as assessed by visual analogue scale (VAS) [ Time Frame: 28 Days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed and dated informed consent.
  • Patients with the typical presentation of HLA-B27 positive AAU (unilateral, painful anterior uveitis of sudden onset).
  • 2+ anterior chamber cells according to the SUN Working Group criteria, as assessed by slit lamp biomicroscopy.
  • Start of the typical first symptoms of the current attack, defined as the point in time when the patient felt the first sensation of the attack, within the last 72 hours before initiation of treatment with the study medication.
  • Negative pregnancy test for females of childbearing potential (pre menopausal, <2 years post-menopausal, not surgically sterile).
  • Patients with a negative QuantiFERON TB Gold test result.
  • Patients who currently have no clinically apparent symptoms of an HLA B27 associated acute extraocular disorder requiring systemic immunosuppressive therapy.
  • Patients who are willing and able to cooperate with study requirements.

Exclusion Criteria:

  • IOP elevation requiring therapy.
  • Uncontrolled diabetes mellitus and diabetic retinopathy.
  • Patients with a single eye or a pinhole Snellen visual acuity 20/200 or worse in the non study eye.
  • Patients with 1+ or less anterior chamber cells.
  • Patients with 3+ or 4+ anterior chamber cells or hypopyon.
  • Patients in whom the time of the beginning of the current attack can not be determined.
  • Patients exhibiting corneal ulceration or a history of recurrent herpetic keratitis or clinical evidence of herpetic dermatitis.
  • Patients currently treated with topical corticosteroids.
  • Patients treated with systemic immunosuppressive therapy within the last 2 months.
  • Patients treated with a systemically administered TNF-alpha inhibitor within the last 2 months.
  • Pregnant or breast-feeding women or women of childbearing potential, who with their partners refuse to use 2 reliable methods of contraception (including 1 barrier method) during the study.
  • Male patients with a female partner who could become pregnant and who refuse, with their partner, to use 2 reliable methods of contraception (including 1 barrier method) during the study.
  • Patients whose clinical presentation is suggestive for an active bacterial, viral or fungal infection anywhere in the body.
  • Patients with history of recurrent infections, or a clinical presentation suggestive of a chronic infection requiring antimicrobial therapy (e.g. syphilis) including active episodes of serious viral infections by, e.g. herpes simplex, herpes zoster, cytomegalic or hepatitis viruses or clinical signs of fungal infections, such as histoplasmosis, aspergillosis or coccidiomycosis.
  • Patients presenting with higher intraocular pressure in the uveitic eye than in the contralateral eye.
  • Patients with known carrier status of human immunodeficiency virus, hepatitis B or hepatitis C.
  • Patients with a history of demyelinating disease (multiple sclerosis) or optic neuritis.
  • Patients with positive or unclear QuantiFERON TB Gold test result or history of high risk exposure to Mycobacterium tuberculosis.
  • Patients with known coexisting malignancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00823173

Layout table for location information
Tübingen, Baden-Würtemberg, Germany, 72076
Uveitis-Zentrum Franziskus Hospital
Münster, Nordrhein-Westfalen, Germany, 48145
Charité Humboldt University
Berlin, Germany, 13353
Sponsors and Collaborators
Layout table for investigator information
Study Chair: Manfred Zierhut, MD Universitäts-Augenklinik Tübingen
Layout table for additonal information
Responsible Party: Sushanta Mallick, Head Clinical Trial Management, ESBATech AG Identifier: NCT00823173    
Other Study ID Numbers: ESBA105CRD04
First Posted: January 15, 2009    Key Record Dates
Last Update Posted: May 26, 2011
Last Verified: September 2010
Keywords provided by ESBATech AG:
scFv antibody fragment
ocular inflammation
Additional relevant MeSH terms:
Layout table for MeSH terms
Uveitis, Anterior
Uveal Diseases
Eye Diseases
Iris Diseases